» Collaborative Research » Ongoing Research Projects » Research PROTEOBLOOD

SMA-TB Financing: The project has been co-financed at 65% by the European Regional Development Fund (ERDF) through the Interreg V-A Spain-France-Andorra Programme (POCTEFA 2014-2020). Reference number: EFA360/19 PROTEOBlood
Duration: June 2019 – June 2022
Web: http://proteoblood.eu/



Consortium description

Researchers from universities, research centers, and companies in France and Spain have joined together to create a French-Spanish cooperative network for the analysis of proteinopathies and the development of individualized therapies in hematological cancers. This network will investigate protein homeostasis in two prevalent subtypes of leukemia and lymphoma and develop personalized treatments to cure them.

  • The coordinator of this network is Dr. Gael Roué, from the Josep Carreras Leukaemia Research Institute, with the collaboration of Dr. Pablo Menéndez.
  • Experimental Haematology Unit of the Vall d’Hebron Institute of Oncology (VHIO), led by Dr. Valcárcel
  • French Institute of Health and Medical Research (INSERM), led by Jean-Emmanuel SARRY
  • Association Centre for Cooperative Research in Biosciences - CIC bioGUNE with researcher Mª Rosa Barrio
  • West Occitania branch of the French National Centre for Scientific Research (CNRS), with Pierre Lutz
  • ANAXOMICS Biotech, Spanish biotechnology company, with Judith Farrés
  • Pharmaceutical Chemistry Group of the Sarrià Institute of Chemistry (IQS), with José Ignacio Borrell.

Project Description

Significant advances have been made recently in the diagnosis and selective treatment of some blood cancers. However, most of these cancers remain incurable. Much evidence suggests a link between imbalances in protein homeostasis and the development of some subtypes of leukemia and lymphoma. The study of this phenomenon requires highly specialized knowledge and represents a fundamental economic and research challenge, which institutions cannot address efficiently on an individual basis.

PROTEOblood's goal is to optimize, share and exploit a set of cutting-edge technologies and resources through the coordination of these entities, for the study of protein homeostasis in two prevalent subtypes of leukemia and lymphoma, and to generate innovative tools and technologies transferable to the development of personalized medicines against these diseases.

To this end, the network will bring together a collection of study models derived from patients (organoids and xenografts) with the capacity to recreate the tumor microenvironment ex vivo. State-of-the-art proteomics approaches, associated with systems biology analysis and small molecule design, will allow the complete characterization of proteinopathies and the development of effective and safe therapies to validate in organoid and xenograft collections. PROTEOblood will thus promote technological development, cross-border cooperation, and knowledge sharing, easing the optimization of existing infrastructures and resources of all entities.

As PROTEOblood's partners possess complementary capacities illustrated by co-authorship in publications, patents, and licenses, this project will undoubtedly increase the competitiveness and internationalization of POCTEFA's regions.